GW PHARMA

Cannabis Medicines To Be Given To Babies In UK Trial

A groundbreaking new trial in the United Kingdom has recruited a newborn baby to be given cannabis-derived medicines to help reduce the impact of seizures and brain damage. A newbo...

The Global CBD Industry

CBD is one of the compounds found within the Cannabis plant that everyone's talking about.INC. called CBD the "next gold rush." Biotech firms are using it to develop treatments for...

European Commission Approves Epidiolex

LONDON and CARLSBAD, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW", "the Company" or "the Group"), world leader in discovering, developing ...

How Brexit is Impacting the UK Cannabis Industry

What is happening to the UK cannabis industry during this time of governmental chaos?'Brexit means British Exit'… but what does that actually mean? You may have pondered this que...

GW Pharma Announces Q3 Sales of $86 Million

GW Pharma provides its Q3 financial results ending September 30th, 2019 GW Pharmaceuticals (NYSE:GWPH), the world leader in the discovery, development and commercialization of cann...

GW Pharma Releases Unaudited 2019 Results

GW Pharmaceuticals has provided preliminary, unaudited results for the fourth quarter of 2019 and the year as a whole. GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in th...

GW Pharma Submits New Drug Application For Tuberous Sclerosis

GW Pharma has submitted a New Drug Application to expand Epidiolex to include the treatmet of Tuberous Sclerosis Complex (TSC).GW Pharmaceuticals (NASDAQ:GWPH), the world leader in...

GW Pharmaceuticals Regains Exclusive Rights to Sativex

GW Pharmaceuticals announces they now have exclusive commercialisation rights to Sativex in the UK from BayerGW Pharmaceuticals plc (GW) and Bayer plc, the life science company, to...